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CHAPTER 10
DECREASED PLATELET COUNT PRECEDES
CMV ANTIGENEMIA AFTER LIVER TRANSPLANTATION
E.F. de Maar, R.J. Porte, M.C. Harmsen, W.J. van Son, A.P. van den Berg,




In 445 consecutive liver transplant recipients we observed lower platelet counts in
patients with cytomegalovirus (CMV) infection. This significant difference in
platelet counts (27x103/mm3, P < 0.05) between patients with and without CMV
infection was already observed on day 24 postoperatively; 6 days before we observed
CMV antigenemia. Leukocytes also were lower in patients with CMV infection
(difference 1.7 x103/mm3, P < 0.05) but this difference was observed later (mean day
36 postoperatively). Apparently the fact that platelet counts diverge so early
compared to CMV antigenemia and leukocytes points to early systemic effects of
CMV on platelet kinetics. Considering the extensive evidence published on
endothelial activation by CMV, we speculate that early relative thrombocytopenia
reflects CMV-induced endothelial activation.
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10.1  INTRODUCTION
Cytomegalovirus (CMV) infection is a frequent complication after solid organ
transplantation. Most patients with symptomatic CMV infection have a self-limiting
CMV syndrome consisting of malaise with fever and arthralgia. If no CMV prophyl-
axis is given CMV infection typically occurs 4 weeks after transplantation [1]. In
symptomatic patients leukocytopenia, thrombocytopenia and elevated serum liver
enzymes have been described. Due to prophylactic or pre-emptive therapy with
ganciclovir lethal CMV infection is rarely seen nowadays. However CMV infection
is not without long-term consequences, since CMV is believed to play an important
role in the development of atherosclerosis, the most important cause of death in
transplant recipients [2, 3, 4]. Although mild thrombocytopenia is well established
as a symptom of CMV infection in transplant recipients, there are no studies that
have systematically studied the changes in platelet count during CMV infection after
liver transplantation. Platelet counts are known to decrease in many acute viral
diseases and platelets are known to be involved in diseases characterized by acute and
chronic endothelial activation. In the current study the chronology of changes in
platelet count, leukocyte count and CMV infection were studied in liver transplant
recipients with and without CMV infection.
10.2  METHODS
All orthotopic liver transplantations performed in our center between June 1992 and
July 2002 were analyzed. With regard to the incubation period of CMV, retransplant
procedures within 1 month of the first transplant were counted as a single transplant
episode.
The presence of CMV infection was diagnosed and monitored by the pp65 CMV
antigenemia assay [5-9] performed weekly, starting on postoperative day 10 until 12
weeks after transplantation or until CMV antigenemia became negative. Briefly,
peripheral blood leukocytes were isolated, cytocentrifuged and incubated with a
mixture of monoclonal antibodies directed against a 65 kD CMV antigen, followed
by immunoperoxidase staining. The number of antigen-positive cells and total
number of leukocytes were counted on two different cytospots and results were ex-
pressed as the number of pp65 positive cells per 50.000 leukocytes.   
Recipient CMV-status before transplantation was assessed with CMV-IgG titers.
IgM and IgG CMV antibodies were measured quantitatively by ELISA using late stage
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CMV-infected fibroblasts as antigens [9]. Primary CMV infections were defined as
infections in seronegative recipients receiving a transplant from a seropositive donor
(pos-neg donor-recipient serology combinations). Secondary CMV infections were
defined as infections in seropositive recipients (pos-pos or neg-pos serology
combinations).
Before 1997 high-risk patients (i.e. pos-neg) received prophylaxis with
acyclovir; as off 1997 ganciclovir was given. High-dose ganciclovir or foscavir was
started in patients who developed CMV antigenemia.
Mean platelet count and leukocyte count were calculated at 2 day intervals for
all patients. All CMV antigenemia levels were analyzed between day 0 and day 100,
platelet counts and leukocyte counts were analyzed between day 0 and day 50 post-
operatively. In order to avoid bias by more frequent determinations of platelet count
or leukocyte count in some (e.g. sicker) patients, multiple measurements on the same
day were averaged to one value before further analysis. Likewise missing platelet
counts or leukocyte counts were interpolated.
Data are expressed as mean ± SEM, unless indicated otherwise. Differences were
assessed using Student’s t-test and were corrected according to Bonferroni in case of
multiple comparisons.
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10.3  RESULTS
All 461 consecutive liver transplants performed in our center in the study period
were analyzed. After combining early retransplants with previous transplants, 445
transplant cases remained. Median age of the recipients was 34 years (range 0-68
years), 52% were males.
Of the 445 cases 208 (47%) had CMV infection as diagnosed by a positive CMV
pp65-antigenemia assay. Within these 208 patients 119 (57%) had low maximal
antigenemia levels (CMV antigenemia £  10 positive granulocytes/50.000
leukocytes), 58 (28%) moderate antigenemia levels (CMV antigenemia between 10
and 100) and 31 (15%) high levels (CMV antigenemia ≥ 100 positive granulocytes/
50.000 leukocytes) (table 10.1). 28% were primary and 71% were secondary
infections. CMV infection was detected at a mean of 30 days after transplantation.
A significant difference in the platelet counts was found from day 24 after
transplantation, with a platelet count that was 27x103/mm3 lower in patients with
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CMV compared to negative patients (P < 0.001, figure 10.1). This difference was due
to a lack of further increase in platelet count in patients with CMV infection. In fact,
mean platelet count in the CMV antigenemia positive patients remained within the
normal range. Absolute thrombocytopenia (i.e. < 50x103/mm3) was seen in 19% of
the CMV antigenemia positive patients compared with 16% of the CMV antigenemia
negative patients (n.s.).
Subgroup analysis of the recipient serology status had no effect on the time course
of the platelet count for patients with or without CMV-infection. In contrast to the
platelet count, the leukocyte count in the two groups did not differ until day 36, after
which values became significantly lower in CMV positive patients, with a mean
difference of 1.7x103/mm3 (P < 0.05, figure 10.2).
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10.4  DISCUSSION
In this study we observed significantly lower platelet counts in liver transplant
recipients with CMV infection compared to liver transplant recipients without CMV
infection. The difference in platelet counts could already be observed several days
before onset of a detectable CMV infection. We also observed lower leukocyte
counts, but this was observed 12 days later than the lower platelet counts.   
During the first days after liver transplantation early thrombocytopenia can be found
in the majority of patients [11]. Rapid increase of platelet count occurs towards the
end of the first week and a stable platelet count, within the normal range, is normally
achieved within 3-4 weeks [12]. Several factors play a role in the development of
this early thrombocytopenia after liver transplantation. Massive blood loss during
the operation and disseminated intravascular coagulation probably play a role. An at-
tractive hypothesis for the pathogenesis of early thrombocytopenia is the sequestra-
tion of thrombocytes in the sinusoids of the liver by endothelial activation immedi-
ately after reperfusion of the liver [13, 14]. Platelets sequester in the liver immediate
after reperfusion and induce apoptosis of sinusoidal endothelial cells [14]. Platelet
sequestration in the liver correlates with the duration of cold ischemia [15].
Upregulated adhesion molecules such as selectins play an important role in the
adhesion of platelets to endothelial cells immediately after reperfusion. For example
platelet sticking can be reduced by inhibition of selectin receptor-mediated adhesion
by sialyl Lewis X oligosaccharide (sLex) [13].
We did not find a relation between CMV infection and early thrombocytopenia.
However after postoperative day 24 we observed a difference in platelet counts be-
tween patients with and patients without cytomegalovirus infection. This difference
is caused by a greater increase in platelet counts in the patients without CMV infec-
tion compared with patients with CMV infection. The difference in platelet counts
was seen 6 days before the CMV antigenemia assay became positive. Also the leuko-
cyte counts were lower in patients with CMV infection, but this difference appeared
later at a mean of 36 days postoperatively.
The kinetics of these events is interesting. Apparently CMV has an effect on
thrombocytes before we can detect the virus in blood with the pp65-antigenemia
assay. The same may be the case with other assays like nucleic acid sequence-based
amplification (IE1-NASBA) [16, 17]. This indicates that CMV infection is an early
phenomenon after transplantation, and that dissemination via the blood, and the
appearance of antigenemia or viral mRNA in blood, are relatively late. What we can
trace back in the blood to an active CMV infection represents only the tip of the ice-
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berg, since it is an incomplete reflection of the pathophysiological process that takes
place [18, 19].
We can speculate on the pathophysiological mechanisms explaining the lower
platelet levels. In our opinion, infection of endothelial cells takes place after reac-
tivation of the virus. Subsequent to infection of endothelial cells, CMV can spread
hematogenously to different parts of the body. Circulating cytomegalic endothelial
cells probably play an important role in the spreading of the virus. Polymorpho-
nuclear leukocytes take up pp65 from the infected endothelial cells. The pp65 anti-
genemia assay will become positive and reflects the endothelial viral load. Before
appearance of pp65 positive leukocytes in the blood, infection of endothelial cells
has already begun and can affect thrombocytes. For example there is evidence that
Cytomegalovirus infection can induce tissue factor on the endothelial cell surface
[20, 21, 22]. Tissue factor is a main activator of the clotting cascade. Moreover, the
viral envelope contains tissue factor and procoagulant phospholipids that cause
activation of the clotting cascade even before viral proteins are synthesized [23, 24].
Furthermore CMV induces the release of Von Willebrand factor (VWF) from
endothelial cells. VWF is an essential bridging molecule for platelet aggregation and
adhesion and acts as a carrier for factor VIII increasing the half-life of factor VIII
five-fold [25, 26]. Additionally CMV-induced adhesion molecules can augment the
adhesion of platelets to infected endothelial cells very early during CMV infection
[27].
Besides sequestration of thrombocytes due to activation of the clotting system
or by interaction with endothelial cells, decreased production of platelets is con-
ceivable. For example decreased production of thrombopoetin has been suggested
[28, 29]. Thrombocytopenia as shown in our study is a very early phenomenon in
CMV infection and a decrease in production of thrombopoetin takes time to have
effect in decreasing thrombocyte counts. Thus a CMV-effect on thrombopoiesis
would point to an even earlier impact of CMV-infection after transplantation than
an effect on platelet clearance. 
10.5  CONCLUSIONS
This is the first large clinical study confirming that CMV infection in liver transplant
recipients is associated with significantly lower platelet counts. This difference in
platelet counts between liver transplant recipients with and without CMV infection
was observed even before detectable CMV antigenemia and two weeks before dif-
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ferences in leukocyte counts. Apparently CMV infection occurs very early and more
widespread than usually realized, and in blood we only recognize the tip of the iceberg
relatively late during the infection. Sequestration of platelets caused by increased
adhesion to infected endothelial cells and intravascular pooling may be responsible
for the early difference in platelet counts.   
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